Alcohol Use Disorder — Diagnosis and Severity

minorv2 · 5,528 words · 23 of 23 citations verified against knowledge base

Latest — unverified, needs review

These items come from live Google Search via Gemini grounding. They are NOT in the canonical knowledge base — they require human review before they can enter the verified body.

controversies · captured 2026-05-17 18:53:22 · status: pending-review

As of today, several active clinical, scientific, and policy controversies exist regarding the diagnosis and severity of Alcohol Use Disorder (AUD). These debates involve the diagnostic criteria themselves, the efficacy of various treatments, and broader public health policies.

1. The Diagnostic Criteria and Severity Spectrum of AUD

A key controversy in the diagnosis of AUD revolves around the shift from the DSM-IV categories of "alcohol abuse" and "alcohol dependence" to the DSM-5's single dimensional classification of AUD with a severity gradient (mild, moderate, and severe).

Major Positions:

  • Position 1: The DSM-5's single continuum is an improvement. Proponents argue that this model better reflects the reality that AUD is a spectrum disorder and that problems can worsen or improve over time. This approach allows for earlier identification and intervention before severe dependence develops.
  • Position 2: The DSM-5 criteria may lead to diagnostic and treatment gaps. Some research suggests that the requirement of at least two criteria for a mild AUD diagnosis may result in individuals who would have been diagnosed with "alcohol abuse" under DSM-IV now receiving no diagnosis at all, potentially losing access to treatment.
  • Position 3: Discrepancies between DSM-5 and ICD-10 create confusion. While there is high concordance for severe AUD and for those with no diagnosis, significant differences exist for mild and moderate cases between the two major diagnostic manuals. This has implications for clinical practice, research, and billing for services.

Who Holds Each Position:

  • Position 1: The American Psychiatric Association, which publishes the DSM, and researchers who see the spectrum model as more clinically nuanced.
  • Position 2: Some researchers and clinicians who are concerned about the potential for under-diagnosis in certain populations.
  • Position 3: Clinicians and researchers who work across different healthcare systems that may use one manual over the other, and public health officials concerned with diagnostic consistency.

Most Recent Primary Source:

  • A 2020 study published in medRxiv examined the clinical characteristics associated with the three DSM-5 AUD severity levels, suggesting that severity levels might be used to determine the intensity of interventions.
  • A 2015 article in Healio highlighted the discrepancies between DSM-5 and ICD-10 for mild and moderate AUD and the potential implications for treatment access.

2. The Efficacy of Psychedelic-Assisted Therapy for AUD

There is significant interest and debate surrounding the use of psychedelics, particularly psilocybin, in combination with psychotherapy for the treatment of AUD.

Major Positions:

  • Position 1: Psychedelic-assisted therapy is a promising breakthrough treatment. Proponents point to early clinical trials suggesting that psilocybin can lead to rapid and sustained reductions in drinking behavior. Some qualitative studies also suggest that psilocybin can reduce alcohol cravings and diminish shame-based thought patterns associated with AUD.
  • Position 2: Enthusiasm for psychedelic-assisted therapy for AUD is outpacing the evidence. Skeptics argue that much of the existing research is flawed, with methodological weaknesses such as small sample sizes, issues with blinding, and inconsistent results. They emphasize that while psychedelics may have a role in treating other psychiatric conditions, their efficacy for AUD is not yet well-established.

Who Holds Each Position:

  • Position 1: Researchers at institutions like Johns Hopkins and Imperial College London who have conducted some of the initial promising trials, as well as advocacy groups for psychedelic medicine.
  • Position 2: Some addiction psychiatrists and researchers who caution against hype and advocate for prioritizing existing, evidence-based treatments for AUD.

Most Recent Primary Source:

  • A secondary analysis of a randomized controlled trial published in the American Journal of Psychiatry in January 2025 suggested that psilocybin-assisted therapy led to durable shifts in personality traits associated with AUD.
  • A November 2025 article in Psychology Today featured addiction psychiatrists from Columbia University who argued that the evidence for psilocybin's role in treating AUD is limited and flawed, and that enthusiasm has outpaced the data.

3. Comparative Effectiveness of Naltrexone Formulations

Naltrexone is an FDA-approved medication for AUD that comes in an oral daily pill and a long-acting monthly injection. There is ongoing discussion about the comparative effectiveness of these two formulations.

Major Positions:

  • Position 1: Extended-release injectable naltrexone leads to better treatment persistence. Proponents of the injectable form argue that it improves adherence, which is a significant challenge with the daily oral medication. A recent meta-analysis supports the view that treatment persistence is higher with the extended-release injection.
  • Position 2: Oral and extended-release injectable naltrexone have comparable effectiveness on drinking outcomes. Recent randomized clinical trials have found no significant difference between the two formulations in reducing heavy drinking days. This suggests that the choice of formulation should be guided by factors like patient preference and insurance coverage.

Who Holds Each Position:

  • Position 1: Researchers and clinicians who prioritize treatment adherence and see the long-acting formulation as a way to overcome this barrier.
  • Position 2: Researchers who have conducted head-to-head clinical trials and advocate for a patient-centered approach to choosing medication.

Most Recent Primary Source:

  • A meta-analysis published in the Psychopharmacology Bulletin in March 2026 found that extended-release naltrexone was associated with higher treatment persistence compared to oral naltrexone, though there were no significant differences in healthcare utilization.
  • A randomized clinical trial published in JAMA Internal Medicine in June 2025 concluded that when initiated at hospital discharge, oral and extended-release injectable naltrexone did not differ in their effectiveness in reducing heavy drinking days.

4. The Role of Harm Reduction in AUD Treatment

The traditional goal of AUD treatment has been complete abstinence from alcohol. However, there is a growing debate about the role of harm reduction strategies, such as moderation or controlled drinking.

Major Positions:

  • Position 1: Abstinence should be the primary goal of AUD treatment. This long-standing view is held by many traditional treatment programs and mutual-help groups like Alcoholics Anonymous. The argument is that for many with severe AUD, any level of drinking is risky and can lead to relapse.
  • Position 2: Harm reduction, including moderation, is a valid and effective treatment goal for some individuals. Proponents of this view argue that a focus on reducing the negative consequences of drinking can be a more achievable and motivating goal for some people with AUD. This approach may also engage individuals who are not ready or willing to commit to abstinence.

Who Holds Each Position:

  • Position 1: Traditional addiction treatment providers and proponents of 12-step programs.
  • Position 2: Harm reduction advocates, some addiction researchers, and clinicians who favor a more individualized approach to treatment.

Most Recent Primary Source:

  • An article in the American Journal of Bioethics from October 2020 discusses the philosophical underpinnings of harm reduction, distinguishing between a "technocratic" approach based on the unenforceability of prohibition and a "deliberative" approach based on reasonable disagreement about controversial behaviors.
  • The Recovery Research Institute at Massachusetts General Hospital highlights that moderation appears to be a viable pathway to AUD remission for some individuals.

5. Policy Disagreements on Alcohol Control and Public Health Messaging

There are significant controversies at the policy level regarding the best strategies to reduce alcohol-related harm and how to communicate the health risks of alcohol consumption to the public.

Major Positions:

  • Position 1: Stronger government policies are needed to reduce alcohol consumption and related harms. Public health advocates and organizations like the World Health Organization and the American Public Health Association support evidence-based policies such as increasing alcohol taxes, restricting availability, and banning alcohol advertising.
  • Position 2: The alcohol industry and some policymakers oppose stricter regulations. These groups often argue that such policies are paternalistic and harm the economy. They may also promote industry-funded "responsible drinking" campaigns, which public health advocates argue can undermine more effective policies.
  • Position 3: The idea that moderate drinking is healthy is outdated and should be abandoned. A growing body of scientific evidence suggests that even low levels of alcohol consumption increase the risk of certain cancers and other health problems. This has led some public health bodies and researchers to call for a revision of dietary guidelines to reflect that less alcohol is always better.
  • Position 4: Public health guidelines on alcohol should be less restrictive. In a recent reversal, the U.S. has loosened its guidance on alcohol consumption, moving away from specific daily limits and toward a more general recommendation to "consume less alcohol for better overall health." This move has been criticized by some public health experts as a step backward that aligns with alcohol industry interests.

Who Holds Each Position:

  • Position 1: Public health organizations and researchers focused on population-level interventions.
  • Position 2: The alcohol industry and its trade associations, as well as some political groups who favor less government regulation.
  • Position 3: A growing consensus among cancer researchers, epidemiologists, and public health scientists.
  • Position 4: The U.S. Departments of Health and Human Services and Agriculture, as reflected in the 2025-2030 Dietary Guidelines for Americans.

Most Recent Primary Source:

  • The 2025-2030 Dietary Guidelines for Americans, released in January 2026, which revised the U.S. government's recommendations on alcohol consumption.
  • A January 2025 update from the CDC on moderate alcohol use, which states that even moderate drinking may increase the risk of death and other alcohol-related harms compared to not drinking.

6. Emerging Pharmacotherapies for AUD

While there are several FDA-approved medications for AUD, there is a recognized need for more effective and appealing treatment options. This has led to research into novel pharmacotherapies, with GLP-1 receptor agonists (like semaglutide, used for diabetes and weight loss) being a particularly active area of investigation.

Major Positions:

  • Position 1: GLP-1 receptor agonists show promise as a new treatment for AUD. Proponents point to preclinical data, retrospective studies, and early clinical trial results suggesting that these medications may reduce alcohol consumption. This has generated excitement about a potential new class of drugs for AUD.
  • Position 2: More rigorous clinical trials are needed to confirm the efficacy and safety of GLP-1 receptor agonists for AUD. While early results are promising, definitive evidence from large, randomized, placebo-controlled trials is still needed before these medications can be considered a standard treatment for AUD.

Who Holds Each Position:

  • Position 1: Researchers and clinicians who are encouraged by early findings and are actively studying these medications for AUD.
  • Position 2: The broader scientific and regulatory community, including the FDA, which will require robust data from Phase 3 clinical trials before considering approval for this indication.

Most Recent Primary Source:

  • A Phase 3 clinical trial to evaluate the efficacy and safety of semaglutide in U.S. veterans with AUD is currently underway, as detailed on ClinicalTrials.gov.
  • A November 2025 article from MMIT highlights the significant unmet need in AUD treatment and the promising results of off-label use of GLP-1 agonists in reducing alcohol use.
regulatory · captured 2026-05-17 18:52:37 · status: pending-review

As of May 2024, the diagnosis and management of Alcohol Use Disorder (AUD) are guided by established diagnostic criteria, FDA-approved medications, and clinical practice guidelines from leading professional organizations and government agencies.

Diagnosis and Severity of Alcohol Use Disorder

The diagnosis of Alcohol Use Disorder is based on criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). A diagnosis of AUD can be made when a patient meets at least two of the 11 specified criteria within a 12-month period. The severity of the disorder is graded based on the number of criteria met:
* Mild: 2-3 criteria
* Moderate: 4-5 criteria
* Severe: 6 or more criteria

FDA-Approved Medications for Alcohol Use Disorder

The U.S. Food and Drug Administration (FDA) has approved several medications to treat alcohol dependence and prevent relapse. These medications are a key component of comprehensive treatment plans that also include counseling and behavioral therapies.

Medications for Alcohol Abstinence and Relapse Prevention:

  • Acamprosate: This medication is for patients who have already stopped drinking and want to maintain abstinence. It works by reducing the negative symptoms associated with prolonged abstinence, such as insomnia, anxiety, and restlessness.
  • Naltrexone: Available in both oral and long-acting injectable forms, naltrexone helps to reduce heavy drinking and prevent relapse. It works by blocking the euphoric effects and feelings of intoxication from alcohol. The FDA has approved both oral naltrexone and an extended-release injectable version.
  • Disulfiram: This medication is used to help maintain abstinence and is for individuals who have already undergone detoxification. It works by causing unpleasant physical reactions, such as nausea and heart palpitations, if alcohol is consumed.

Active Clinical Practice Guidelines

Several professional organizations have issued clinical practice guidelines for the diagnosis and treatment of Alcohol Use Disorder.

  • American Psychiatric Association (APA): The APA's "Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder" (2018) provides evidence-based recommendations for the use of medications in the treatment of AUD. The guideline strongly recommends naltrexone and acamprosate for patients with moderate to severe AUD.
  • American Society of Addiction Medicine (ASAM): The "ASAM Clinical Practice Guideline on Alcohol Withdrawal Management" (2020) offers guidance on the safe and effective management of alcohol withdrawal in various treatment settings. This guideline focuses on the initial stabilization phase before long-term treatment.
  • American Academy of Child and Adolescent Psychiatry (AACAP): While there isn't a recent standalone guideline specifically for AUD, the AACAP's "Practice Parameter for the Assessment and Treatment of Children and Adolescents With Substance Use Disorders" (2005, reaffirmed in 2011) provides a framework that includes alcohol.

Recent Position Statements and Resources from Federal Agencies

  • Substance Abuse and Mental Health Services Administration (SAMHSA): SAMHSA provides numerous resources for clinicians and the public, including Treatment Improvement Protocols (TIPs). While some TIPs covering alcohol are older, they remain a valuable resource. SAMHSA also issues advisories and data reports on alcohol consumption and its consequences.
  • National Institute on Alcohol Abuse and Alcoholism (NIAAA): The NIAAA is a leading authority on alcohol research and treatment. Their website, the "NIAAA Alcohol Treatment Navigator," is a comprehensive resource designed to help individuals find evidence-based alcohol treatment. The NIAAA also provides clinical guidance for healthcare professionals, including a guide for assessing and managing alcohol-related problems in primary care settings.
  • National Institute on Drug Abuse (NIDA): While NIDA's primary focus is on other substances, their research often includes alcohol, particularly in the context of polysubstance use. NIDA's publications and research findings contribute to the broader understanding of addiction and its treatment.
whats-new · captured 2026-05-17 18:52:22 · status: pending-review

As of mid-May 2026, there have been significant developments in the past six months regarding Alcohol Use Disorder (AUD), particularly in clinical trial endpoints, national dietary guidelines, and promising new research into pharmacological treatments. No new medications for AUD have been approved by the FDA, nor have there been any recent label changes, recalls, or warnings issued.

Shift in Clinical Trial Endpoints and Regulatory Guidance

In a move to facilitate the development of new treatments for AUD, the U.S. Food and Drug Administration (FDA) has signaled a significant shift in how the success of clinical trials is measured. While this development occurred just outside the six-month window, its impact is ongoing.

In February 2025, the FDA's Center for Drug Evaluation and Research (CDER) qualified a new tool for use as a primary endpoint in clinical trials for AUD medications. This tool allows for the assessment of a two-level reduction in the World Health Organization's (WHO) risk drinking levels, moving beyond the traditional primary endpoints of complete abstinence or no heavy drinking days. This change is intended to encourage the development of new therapies by recognizing meaningful reductions in alcohol consumption as a valid clinical outcome.

Further supporting this shift, the Fiscal Year 2026 Labor-HHS-Education Appropriations package included a directive for the FDA and the National Institute on Drug Abuse (NIDA) to collaborate on establishing alternative clinical trial endpoints for substance use disorders, including AUD, that go beyond complete abstinence.

Updated National Dietary Guidelines on Alcohol Consumption

A major policy shift occurred in January 2026 with the release of the 2025-2030 Dietary Guidelines for Americans by the U.S. Departments of Health and Human Services (HHS) and Agriculture (USDA). The new guidelines have removed the previous recommendation of limiting alcohol intake to one drink per day for women and up to two drinks per day for men. The updated advice is now a broader recommendation to "consume less alcohol for better overall health."

This change has been met with some concern from health professionals who worry the lack of specific limits may lead to confusion and potentially increased alcohol consumption. The guidelines also specify that certain individuals, such as those recovering from AUD or who are unable to control their drinking, should not consume alcohol at all.

Promising Results for a New Pharmacological Treatment

In a significant development for potential new treatments, the results of a major clinical trial were published on April 30, 2026. The randomized controlled trial, involving scientists from the National Institutes of Health (NIH), found that the GLP-1 receptor agonist semaglutide, when combined with cognitive behavioral therapy, significantly reduced heavy drinking days in individuals with both obesity and AUD. Participants who received semaglutide saw a 13.7% greater reduction in heavy drinking days compared to the placebo group. While not yet FDA-approved for AUD, this research has generated considerable interest in the potential for GLP-1 medications to treat substance use disorders.

Several other clinical trials for new AUD medications are currently underway, investigating drugs such as brenipatide, apremilast, and suvorexant.

No New Consensus Statements or Major Regulatory Shifts from Other Agencies

There have been no new clinical guidelines or consensus statements on the diagnosis or severity of AUD issued by major medical organizations in the past six months. The diagnostic criteria for AUD, as outlined in the DSM-5, remain the standard.

The Substance Abuse and Mental Health Services Administration (SAMHSA) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA) have not released any major regulatory or policy shifts regarding AUD diagnosis and severity in the last six months. Their current strategic plans were established prior to this period. SAMHSA continues to focus on prevention and treatment access through its ongoing programs.

Alcohol Use Disorder: Diagnosis, Severity, and the Gap Between Identification and Care

A comprehensive clinical and research reference synthesizing current evidence on DSM-5 criteria, screening instruments, severity stratification, and diagnostic equity.


Overview — Why Diagnostic Precision Matters

Alcohol use disorder (AUD) is among the most prevalent and undertreated conditions in medicine. Approximately 10.9% of U.S. adults meet criteria for AUD, yet in a cohort of 114,511 individuals who screened positive for unhealthy alcohol use, only 10.1% had a formal AUD diagnosis documented in their electronic health record (EHR) [1]. That gap — between the person who drinks in ways that harm their health and the person who receives a diagnosis and a treatment plan — is not a minor measurement artifact. It is a systemic failure with documented consequences.

Why does a formal diagnosis matter? Because it is a gateway. In the same large cohort, receiving an AUD diagnosis increased the adjusted odds of being prescribed medication (disulfiram, acamprosate, or naltrexone) by more than tenfold (adjusted odds ratio [aOR] = 10.68; 95% CI: 9.68–11.79) and the odds of receiving psychotherapy by over 50% (aOR = 1.57; 95% CI: 1.46–1.69) [1]. The act of diagnosis is itself a clinical intervention.

Understanding what that diagnosis means — how it is made, what criteria it rests on, how it is graded by severity, and how it differs from a positive screening result — is therefore not an academic exercise. It is the foundation of equitable, effective care.

The DSM-IV to DSM-5 Transition

Before 2013, the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) divided alcohol-related pathology into two separate categories: alcohol abuse (a pattern of harmful use without physical dependence) and alcohol dependence (physiological and behavioral dependence). These were treated as distinct diagnoses, not points on a continuum.

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) collapsed this binary into a single dimensional disorder — AUD — assessed across 11 criteria and graded by severity [2] [3]. One criterion was added that had no DSM-IV equivalent: craving. One criterion was removed: recurrent legal problems related to alcohol. The remaining criteria were reorganized from the former abuse and dependence clusters.

This restructuring has direct implications for prevalence research. A patient who met DSM-IV criteria for alcohol abuse (but not dependence) may now meet criteria for mild AUD under DSM-5 — or may not, depending on which criteria they endorse. Conversely, some DSM-IV dependence cases map cleanly to DSM-5 severe AUD, while others do not. When citing prevalence figures from studies conducted before 2013, readers should note that the diagnostic framework changed; DSM-IV and DSM-5 estimates are not directly comparable [4].


The 11 DSM-5 Criteria

The criteria are grouped here by conceptual domain, though the DSM-5 does not formally weight them — a point that has itself been criticized (see Evidence Gaps, below).

For each criterion, the source-language framing is presented first, followed by a plain-English translation and a brief clinical illustration.


Domain 1: Impaired Control

Criterion 1 — Larger/Longer Use Than Intended
"Alcohol is often taken in larger amounts or over a longer period than was intended."
The person sets out to have two drinks and regularly has six, or plans to drink only on weekends and finds the pattern expanding. This criterion captures the loss of the internal "stop" signal. In a prospective cohort using SCID-IV-RV assessment, this was among the more commonly endorsed criteria (9.0%) in a young adult sample [4].

Criterion 2 — Persistent Desire or Unsuccessful Efforts to Cut Down
"There is a persistent desire or unsuccessful efforts to cut back or control alcohol use."
The person has tried to stop or reduce — perhaps many times — and has not been able to sustain the change. This is distinct from simply not wanting to stop; it requires that the person has made attempts that failed.

Criterion 3 — Great Deal of Time Spent
"A great deal of time is spent in activities necessary to obtain alcohol, use alcohol, or recover from its effects."
When obtaining, using, and recovering from alcohol begins to consume a significant portion of the person's day, this criterion is met. In severe presentations, this can mean that most waking hours are organized around alcohol.

Criterion 4 — Craving (New in DSM-5; not present in DSM-IV)
"Craving, or a strong desire or urge to use alcohol."
This criterion was added to DSM-5 based on neuroscientific evidence that craving reflects a distinct neurobiological process — incentive salience — separate from physical dependence. It has also been the subject of criticism: craving is subjective, difficult to operationalize reliably, and may overlap with normal desire in social drinkers. The addition of craving as a criterion has been questioned in the literature, and its contribution to diagnostic validity remains an open question (see Evidence Gaps).


Domain 2: Social Impairment

Criterion 5 — Failure to Fulfill Major Role Obligations
"Recurrent alcohol use resulting in a failure to fulfill major role obligations at work, school, or home."
Missing work due to hangovers, neglecting childcare responsibilities, or failing coursework because of drinking patterns. The impairment must be recurrent, not a single incident.

Criterion 6 — Continued Use Despite Social or Interpersonal Problems
"Continued alcohol use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of alcohol."
The person continues drinking even after arguments with a partner about their drinking, estrangement from family, or loss of friendships — and recognizes the connection between alcohol and these problems. In the SCID-IV-RV cohort, social problems were the second most commonly endorsed criterion at 10.4% [4].

Criterion 7 — Important Activities Given Up or Reduced
"Important social, occupational, or recreational activities are given up or reduced because of alcohol use."
Hobbies abandoned, social events avoided, career opportunities declined — because drinking has become the organizing priority.


Domain 3: Risky Use

Criterion 8 — Use in Physically Hazardous Situations
"Recurrent alcohol use in situations in which it is physically hazardous."
Driving while impaired, operating machinery, or drinking in contexts where impairment creates direct physical risk.

Criterion 9 — Continued Use Despite Knowledge of Physical or Psychological Problems
"Alcohol use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by alcohol."
The person has been told — or knows — that their liver disease, depression, or gastritis is worsened by alcohol, and continues drinking. This criterion requires awareness, not just the presence of a medical problem.


Domain 4: Pharmacological Criteria

Criterion 10 — Tolerance
"Tolerance, as defined by either (a) a need for markedly increased amounts of alcohol to achieve intoxication or desired effect, or (b) a markedly diminished effect with continued use of the same amount of alcohol."
The person who once felt intoxicated after three drinks now requires eight to achieve the same effect — or notices that their usual amount no longer produces the effect it once did. Tolerance requires careful interpretation in younger populations. In a prospective cohort using SCID-IV-RV assessment, tolerance was by far the most commonly endorsed criterion at 50.3% — far exceeding the next most common criterion (social problems at 10.4%). When tolerance was removed from the criterion set, DSM-5 AUD lifetime prevalence dropped from 18.4% to 11.0%, a 40% reduction [4]. This raises important questions about whether tolerance, as currently operationalized, is specific enough to distinguish pathological from physiological adaptation in heavy social drinkers.

Criterion 11 — Withdrawal
"Withdrawal, as manifested by either (a) the characteristic withdrawal syndrome for alcohol, or (b) alcohol (or a closely related substance, such as a benzodiazepine) is taken to relieve or avoid withdrawal symptoms."
Withdrawal symptoms include tremor, sweating, anxiety, nausea, and — in severe cases — seizures or delirium tremens. A person who drinks in the morning to stop shaking meets this criterion even if they have never experienced a formal withdrawal syndrome. Withdrawal is clinically the highest-risk criterion. Within mild-to-moderate AUD (2–5 criteria), the presence of withdrawal was associated with an adjusted hazard ratio of 11.62 (95% CI: 7.54–17.92) for progression to severe AUD, compared to aHR 5.64 (95% CI: 3.28–9.70) for mild-to-moderate AUD without high-risk criteria [2]. Two patients can share the same DSM-5 severity label but have radically different clinical trajectories depending on whether withdrawal is present.


A Note on Criterion Removal

The DSM-IV criterion of recurrent legal problems related to alcohol (e.g., DUI arrests) was removed in DSM-5. This decision was partly driven by evidence that legal consequences are heavily influenced by socioeconomic and racial factors — a person with resources may avoid arrest for the same behavior that results in criminal charges for someone without them. Removing this criterion reduces, though does not eliminate, socially patterned diagnostic bias.


Severity Stratification

The DSM-5 grades AUD severity by criterion count:

Severity Criteria Met Approximate Diagnosis Rate in Screened Cohort
Mild 2–3 6.8% [1]
Moderate 4–5 21.5% [1] (Note: this specific figure could not be independently verified against the source abstract — the underlying study supports the general finding but the exact number should be confirmed before publication)
Severe 6 or more 41.6% [1] (Note: this specific figure could not be independently verified against the source abstract — the underlying study supports the general finding but the exact number should be confirmed before publication)

These cutoffs are clinically useful as shorthand, but the evidence base for the specific thresholds is limited. The 2–3/4–5/6+ boundaries were established by expert consensus rather than empirical validation against treatment outcomes. As [2] demonstrated in a combined cohort of 15,928 individuals, simple criterion counts obscure meaningful heterogeneity within severity bands. A patient with mild AUD (2–3 criteria) who endorses withdrawal has a dramatically worse prognosis than a patient with mild AUD who endorses only tolerance and craving — yet both receive the same severity label.

This has direct clinical implications. The current DSM-5 count-based framework, as [2] explicitly states, "may be improved by emphasizing specific high-risk criteria." Clinicians using severity to guide treatment intensity should assess which criteria are present, not merely how many.

An important caveat on the severity gradient data: The diagnosis rates of 6.8%, 21.5%, and 41.6% cited above come from [1], which operationalized severity using AUDIT-C risk tiers — not DSM-5 criterion counts. These are consumption-based categories, not symptom-based categories. The two systems are not interchangeable, and the apparent severity gradient may partly reflect instrument discordance rather than a true clinical severity gradient (see DSM-5 vs. DSM-IV vs. ICD-11 and Differential Diagnosis sections below).


Remission Specifiers

The DSM-5 includes remission specifiers that clinicians should document in the medical record, as they affect insurance coverage, disability determinations, and treatment planning:

  • Early remission: No criteria for AUD have been met (except craving) for at least 3 months but less than 12 months.
  • Sustained remission: No criteria for AUD have been met (except craving) for 12 months or longer.
  • In a controlled environment: The individual is in an environment where access to alcohol is restricted (e.g., incarceration, residential treatment). This specifier acknowledges that abstinence in a controlled setting does not carry the same prognostic weight as community-based remission.
  • On maintenance therapy: The individual is taking a prescribed medication (e.g., naltrexone, acamprosate) as part of treatment.

Natural history data from a prospective cohort study (cumulative incidence of AUD symptoms from late adolescence to age 42: 58.0%, 95% CI: 52.3–63.8%) found that most individuals do remit — 67.0% by age 42 — but 11–13% show persistent symptoms from late adolescence onward [5]. AUD symptoms peaked at age 24 in this cohort [5]. These natural history data matter for calibrating treatment intensity: for many patients, particularly younger adults, the trajectory is toward remission even without intensive intervention — though the 11–13% with persistent symptoms represent a high-need subgroup requiring sustained engagement.


DSM-5 vs. DSM-IV vs. ICD-11

The same patient can receive different diagnoses depending on which framework is applied. This is not merely a theoretical concern — it directly affects cross-study comparisons and prevalence estimates.

DSM-IV used two separate categories: alcohol abuse (harmful use without dependence) and alcohol dependence (physiological and behavioral dependence). A patient meeting only abuse criteria received a less severe diagnosis with different treatment implications.

DSM-5 collapsed these into a single disorder with 11 criteria. The addition of craving and the removal of legal problems means that some DSM-IV abuse cases become DSM-5 mild AUD, while some DSM-IV dependence cases may not map cleanly to DSM-5 severe AUD. Prevalence estimates from DSM-IV-era studies should not be directly compared to DSM-5 estimates without adjustment [4].

ICD-11 (the International Classification of Diseases, 11th Revision, used internationally and increasingly in U.S. billing) retains a distinction between harmful use (a pattern causing health damage) and alcohol dependence (a cluster of physiological, behavioral, and cognitive phenomena). The ICD-11 dependence syndrome maps most closely to DSM-5 moderate-to-severe AUD, while ICD-11 harmful use overlaps with DSM-5 mild AUD — but the overlap is imperfect [corpus-gap].

A prospective cohort study using SCID-IV-RV assessment found that DSM-5 AUD lifetime prevalence was 18.4% in their sample, while ICD-11 harmful use/dependence prevalence differed — with the specific discrepancy driven substantially by the tolerance criterion, which inflated DSM-5 estimates [4]. Researchers citing prevalence across frameworks should specify which diagnostic system was used and note that the same individual may be classified differently under each.


Screening Tools — AUDIT

Important distinction: Screening tools identify individuals who may have AUD or hazardous drinking patterns. They do not diagnose AUD. A positive screen should prompt formal diagnostic assessment using DSM-5 criteria — it does not replace it.

The Alcohol Use Disorders Identification Test (AUDIT) is a 10-item questionnaire developed by the World Health Organization (WHO) and validated across primary care, emergency department, and community settings. Items cover consumption (frequency, quantity, binge frequency), dependence symptoms (impaired control, morning drinking, guilt), and alcohol-related problems (blackouts, injury, concern from others). Each item is scored 0–4, yielding a total of 0–40.

Scoring thresholds (general adult primary care populations):
- ≥8: Hazardous or harmful drinking; warrants brief intervention
- ≥15: Likely alcohol dependence in most populations; warrants referral for further assessment

A systematic review of 35 studies (N = 79,633) found that AUDIT ≥8 yields a likelihood ratio (LR) of 6.5 (95% CI: 3.9–11) for DSM-5 AUD [6]. Notably, AUDIT performs better for identifying AUD in females (LR 6.9) than males (LR 3.8), a statistically significant difference (p = .003) [6]. This sex difference in diagnostic performance is clinically important: the same cutoff does not carry the same diagnostic weight across sexes.

Population discipline note: These likelihood ratios were derived from studies predominantly in primary care and general adult populations. Performance may differ in emergency departments, specialty addiction settings, or populations with high baseline AUD prevalence.


Screening Tools — AUDIT-C

The AUDIT-C is a three-item abbreviated version of the AUDIT, retaining only the consumption questions (frequency of drinking, typical quantity, and frequency of heavy episodic drinking). It is widely embedded in EHR systems — including the Veterans Health Administration (VHA) — because of its brevity and ease of administration.

Scoring thresholds (general adult populations):
- ≥3 (women) or ≥4 (men): Hazardous drinking; warrants further assessment
- ≥9: Possible alcohol dependence in some health system validation studies

In a head-to-head comparison against a structured diagnostic reference standard, the AUDIT-C demonstrated an area under the curve (AUC) of 0.90 for identifying both problem use and AUD in both males and females, with sensitivity of 0.83–0.89 and specificity of 0.78–0.84 depending on sex and outcome [7]. These are strong screening performance figures.

However, the AUDIT-C is considerably less useful than the full AUDIT for identifying AUD specifically. The likelihood ratio for AUD at standard cutoffs is only 1.8 for males and 2.0 for females [6] — a modest diagnostic signal compared to the full AUDIT's LR of 6.5. The AUDIT-C was designed to detect excessive drinking, not DSM-5 AUD. These are different constructs, and conflating them is a documented source of the apparent "diagnosis gap" in the literature [corpus-gap].

The practical implication: a positive AUDIT-C is a flag that should trigger further assessment, not a diagnosis.


Screening Tools — CAGE, T-ACE, TWEAK, and Others

CAGE is a four-item questionnaire asking about: attempts to Cut down, Annoyance at criticism of drinking, Guilt about drinking, and Eye-opener (morning drinking). It is rapid and widely recognized, but less sensitive than the AUDIT for identifying hazardous drinking without dependence. CAGE was developed before the DSM-5 and does not map onto the 11-criterion framework. It performs best for identifying established dependence and is less useful for detecting mild-to-moderate AUD or hazardous drinking in the absence of dependence symptoms.

T-ACE and TWEAK were specifically validated for use in pregnancy, a population in which any alcohol use carries fetal risk and standard AUDIT cutoffs may not apply. T-ACE asks about Tolerance, Annoyance, Cut down attempts, and Eye-opener. TWEAK asks about Worry, Eye-opener, Amnesia, Kut down attempts, and Pass out. Both tools have been validated for detecting risky drinking in pregnant women, where the clinical threshold for intervention is lower than in the general population.

MAST (Michigan Alcoholism Screening Test) and its shortened versions (SMAST, b-MAST) have been used in outpatient settings and with older adults. The MAST's 25 items cover lifetime consequences of drinking and may be more sensitive for detecting long-standing AUD in older patients, though its length limits routine use.

When to use which tool: The AUDIT remains the best-validated general-purpose screening instrument for primary care adults [6]. The AUDIT-C is appropriate for high-volume EHR-based screening where brevity is essential, with the understanding that positive results require follow-up. T-ACE or TWEAK should be used in pregnancy. CAGE is a reasonable rapid screen in settings where AUDIT is unavailable, but clinicians should recognize its limitations for mild AUD. MAST variants may be appropriate for older adults or forensic settings.


SBIRT — Screening, Brief Intervention, Referral to Treatment

SBIRT (Screening, Brief Intervention, and Referral to Treatment) is a public health framework — not a single tool — that links alcohol screening to a graduated clinical response. The three components are:

  1. Screening: Using a validated instrument (AUDIT, AUDIT-C, or equivalent) to identify individuals with hazardous drinking or possible AUD.
  2. Brief Intervention (BI): For individuals with hazardous or harmful drinking who do not meet AUD criteria, a structured 5–15 minute motivational conversation aimed at reducing consumption. BI is not a treatment for AUD; it is an intervention for risky drinking.
  3. Referral to Treatment (RT): For individuals who screen positive and are subsequently diagnosed with AUD, referral to appropriate treatment — which may include medications for AUD (MAUD), behavioral therapies, or specialty addiction care.

The U.S. Preventive Services Task Force (USPSTF) recommends screening for unhealthy alcohol use in primary care settings in adults 18 and older, including pregnant women, and providing brief counseling interventions to those who screen positive [8]. However, screening is "not always performed consistently or correctly in primary care" [8], and the pathway from positive screen to formal diagnosis to treatment referral breaks down at multiple points.

A critical implementation gap: the SBIRT framework assumes that a positive screen will trigger diagnostic assessment and, if AUD is confirmed, treatment referral. In practice, many clinical systems stop at the screening step — recording an AUDIT-C score in the EHR without completing the diagnostic evaluation needed to generate an ICD code or initiate treatment [corpus-gap]. The result is a documented positive screen with no clinical follow-through.


Screening in Special Populations

Pregnancy: Any alcohol use during pregnancy carries risk of fetal alcohol spectrum disorders. Standard AUDIT cutoffs are not appropriate; T-ACE and TWEAK are the validated tools for this population. The clinical threshold for intervention is lower than in non-pregnant adults.

Adolescents: The CRAFFT (Car, Relax, Alone, Forget, Friends, Trouble) is the most widely validated screening tool for alcohol and drug use in adolescents aged 12–21. Standard adult AUDIT cutoffs should not be applied to this population.

Older adults: Alcohol pharmacokinetics change with age — decreased lean body mass, reduced hepatic metabolism, and increased sensitivity to central nervous system effects mean that older adults experience greater impairment at lower blood alcohol concentrations. Standard AUDIT cutoffs may underestimate risk in this population; modified lower thresholds (e.g., ≥5 rather than ≥8) have been proposed for adults over 65, though the evidence base for specific cutoffs in older adults is less robust than for general adult populations.

College students: High rates of heavy episodic drinking in this population mean that AUDIT-C may flag a large proportion of students without AUD. The full AUDIT or structured DSM-5 assessment is needed to distinguish hazardous drinking from disorder.

Military and veterans: The VHA has implemented AUDIT-C as a universal annual screen for all enrolled patients. VHA data show that survey-based AUD prevalence (10.1%) substantially exceeds EHR-documented diagnosis rates (6.0%), with the largest gaps among patients aged 18–34 (prevalence 22.4% vs. diagnosis rate 6.9%) and Hispanic/Latinx patients (17.7% vs. 7.6%) [2]. Even in a system with mandatory universal screening, the screening-to-diagnosis gap persists.

Racial and ethnic considerations: Screening tool performance has been validated primarily in majority-White populations. The available evidence documents that diagnostic gaps fall along racial and ethnic lines [corpus-gap], but the corpus does not provide criterion-level data on whether specific DSM-5 criteria perform differently across racial/ethnic groups. This is a documented gap in the evidence base.


Differential Diagnosis — Heavy Drinking vs. AUD

The diagnostic threshold for AUD is 2 of 11 criteria within a 12-month period. Below that threshold, a person may drink heavily — even at levels that carry significant health risk — without meeting criteria for the disorder.

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) defines low-risk drinking as no more than 4 drinks on any single day and no more than 14 drinks per week for men; no more than 3 drinks on any single day and no more than 7 drinks per week for women. Drinking above these limits is considered hazardous or at-risk drinking — a target for brief intervention — but does not constitute AUD unless at least 2 DSM-5 criteria are met [3].

This distinction matters clinically. A person who regularly drinks 5–6 drinks per evening but has not experienced loss of control, craving, withdrawal, or functional impairment may be at significant health risk (liver disease, cardiovascular disease, cancer) without meeting AUD criteria. They need intervention — but a different kind than someone with moderate or severe AUD. Conflating hazardous drinking with AUD leads to both over-treatment (applying addiction-focused interventions to someone who needs a brief consumption-reduction conversation) and under-treatment (failing to recognize that some heavy drinkers do meet AUD criteria and need more than brief advice).

A positive AUDIT-C score identifies hazardous drinking. It does not diagnose AUD. The formal diagnosis requires assessing all 11 DSM-5 criteria — ideally using a validated structured instrument such as the Alcohol Symptom Checklist, which demonstrated excellent test-retest reliability in routine primary care (intraclass correlation coefficient [ICC] = 0.82, 95% CI: 0.77–0.85) and can be completed by patients between visits or in waiting rooms [3].


Diagnostic Equity and Recognition Gaps

The underdiagnosis of AUD is not evenly distributed. Multiple data sources document that diagnostic gaps fall systematically along lines of gender, race, ethnicity, age, and socioeconomic status.

In the All of Us cohort, lower odds of AUD diagnosis were documented among females, racial/ethnic minorities, individuals in economically deprived areas, and privately insured patients — despite comparable or higher screening positivity in some of these groups [1]. In the VHA, the largest prevalence-to-diagnosis gaps were among patients aged 18–34 (survey prevalence 22.4% vs. EHR diagnosis rate 6.9%) and Hispanic/Latinx patients (17.7% vs. 7.6%) [2].

These disparities are not explained by differences in actual AUD prevalence. They reflect differential recognition, differential documentation, and differential follow-through from positive screen to formal diagnosis. The consequence is that the patients most likely to be underdiagnosed are also the patients least likely to receive medication or psychotherapy — compounding inequity at every step of the care pathway [1].

The EHR-embedded Alcohol Symptom Checklist — which allows patients to self-report all 11 DSM-5 criteria — represents one structural intervention that may reduce clinician-level recognition bias by standardizing the assessment process [3]. Whether this tool actually narrows equity gaps by race, ethnicity, and sex has not been documented in the available corpus.

A note on the COVID-19 period: The corpus references a collapse in systematic screening during the COVID-19 pandemic, though the available evidence does not provide detailed quantitative data on the magnitude or recovery of screening rates post-pandemic. This is a gap in the current evidence base.


Evidence Gaps and Open Questions

The panel's most important methodological contribution is identifying that the "diagnosis gap" literature conflates two fundamentally different severity constructs: AUDIT-C consumption-based risk tiers and DSM-5 symptom-count criteria. These are not interchangeable. Direct concordance statistics between AUDIT-C tiers and DSM-5 criterion counts are not available in the current evidence base, and the mapping between these two systems remains incompletely characterized.

Several specific open questions deserve attention:

1. Craving as a criterion. The addition of craving to DSM-5 was theoretically motivated but has been questioned on grounds of specificity and operationalization reliability. The corpus does not provide criterion-level reliability data for craving specifically, and the clinical literature has not resolved whether craving adds diagnostic validity beyond the other 10 criteria.

2. Mild AUD validity. A patient who endorses only tolerance and craving — the two criteria most susceptible to over-endorsement in heavy social drinkers — meets criteria for mild AUD. Whether this represents a clinically meaningful disorder or a false positive generated by the criterion structure is an unresolved question. The finding that removing tolerance from the criterion set reduces DSM-5 AUD lifetime prevalence by 40% [4] (Note: this specific figure could not be independently verified against the source abstract — the underlying study supports the general finding but the exact number should be confirmed before publication) suggests that mild AUD prevalence estimates are highly sensitive to how tolerance is operationalized.

3. Does severity classification improve outcomes? The corpus documents that receiving any AUD diagnosis dramatically increases treatment odds [1]. Whether finer-grained severity classification — mild vs. moderate vs. severe, or criterion-specific profiling — leads to differential treatment selection and better outcomes has not been established in the available evidence. The current corpus does not link DSM-5 severity specifiers to treatment assignment or remission rates, leaving the outcome utility of diagnostic precision an important unanswered clinical question.

4. Cross-cultural validity. The DSM-5 criteria were developed primarily from research conducted in Western, high-income populations. The corpus does not address whether the 11 criteria perform equivalently across cultural contexts where alcohol use patterns, social consequences, and help-seeking norms differ substantially.

5. Continuous risk measures as an alternative. The WHO's Risk Drinking Levels framework — which categorizes drinking by grams of pure alcohol per day into low, medium, high, and very high risk — offers a continuous alternative to categorical diagnosis for some purposes, particularly population-level monitoring and brief intervention targeting. Whether continuous risk measures should supplement or partially replace categorical AUD diagnosis for specific clinical purposes is not resolved by the current evidence base.


Summary for Clinical Practice

The evidence supports several clear clinical priorities:

  1. Make the diagnosis. The single most impactful action a clinician can take is to move from a positive AUDIT-C screen to a formal DSM-5 assessment and, where criteria are met, document the diagnosis. The tenfold increase in medication treatment odds associated with a formal diagnosis [1] makes this a high-yield intervention.

  2. Distinguish screening from diagnosis. AUDIT-C identifies; SCID-5-CV (or equivalent structured interview) diagnoses. A positive screen is the beginning of the diagnostic process, not the end.

  3. Assess which criteria are present, not just how many. Withdrawal in a patient with mild AUD (2–3 criteria) carries an adjusted hazard ratio of 11.62 for progression to severe AUD [2]. Criterion identity matters as much as criterion count.

  4. Apply population-appropriate tools. AUDIT for general adults; AUDIT-C for EHR-based universal screening with follow-up; T-ACE or TWEAK in pregnancy; CRAFFT in adolescents; modified thresholds in older adults.

  5. Document remission specifiers. Early vs. sustained remission, controlled environment, and maintenance therapy specifiers affect insurance coverage, disability determinations, and treatment planning.

  6. Attend to equity. Younger patients, women, racial/ethnic minorities, and economically disadvantaged patients are systematically underdiagnosed despite comparable or higher prevalence [y

Verified References

  • [7] Adam, Angéline, Laska, Eugene, Schwartz, Robert P et al. (2025). "Identifying Alcohol Use Disorder and Problem Use in Adult Primary Care Patients: Comparison of the Tobacco, Alcohol, Prescription Medication and Other Substance (TAPS) Tool With the Alcohol Use Disorders Identification Test Consumption Items (AUDIT-C).". Subst Use Addctn J. DOI: 10.1177/29767342251326678 [abstract-verified: partial]
  • [8] Grissom, Maureen O, Reed, Brian C, Starks, Steven M et al. (2024). "Addiction Medicine: Alcohol Use Disorder.". FP Essent. [abstract-verified: partial]
  • [3] Hallgren, Kevin A, Matson, Theresa E, Oliver, Malia et al. (2022). "Practical assessment of DSM-5 alcohol use disorder criteria in routine care: High test-retest reliability of an Alcohol Symptom Checklist.". Alcohol Clin Exp Res. DOI: 10.1111/acer.14778 [abstract-verified: partial]
  • [5] Kerr, Jessica A, Husin, Hanafi Mohamad, Leung, Janni et al. (2025). "The natural history of DSM-5 alcohol-use disorder from late adolescence to middle adulthood in Australia: a prospective cohort study.". Lancet Public Health. DOI: 10.1016/s2468-2667(25)00225-7 [abstract-verified: yes]
  • [2] Miller, Alex P, Kuo, Sally I-Chun, Johnson, Emma C et al. (2023). "Diagnostic Criteria for Identifying Individuals at High Risk of Progression From Mild or Moderate to Severe Alcohol Use Disorder.". JAMA Netw Open. DOI: 10.1001/jamanetworkopen.2023.37192 [abstract-verified: partial]
  • [4] Slade, Tim, Mewton, Louise, O'Dean, Siobhan et al. (2021). "DSM-5 and ICD-11 alcohol use disorder criteria in young adult regular drinkers: Lifetime prevalence and age of onset.". Drug Alcohol Depend. DOI: 10.1016/j.drugalcdep.2021.109184 [abstract-verified: partial]
  • [3] Sheryl Spithoff, Meldon Kahan (2015). "Primary care management of alcohol use disorder and at-risk drinking: Part 1: screening and assessment.". Canadian family physician Medecin de famille canadien. [abstract-verified: partial]
  • [2] Williams, Emily C, Fletcher, Olivia V, Frost, Madeline C et al. (2022). "Comparison of Substance Use Disorder Diagnosis Rates From Electronic Health Record Data With Substance Use Disorder Prevalence Rates Reported in Surveys Across Sociodemographic Groups in the Veterans Health Administration.". JAMA Netw Open. DOI: 10.1001/jamanetworkopen.2022.19651 [abstract-verified: yes]
  • [6] Wood, Evan, Pan, Jeffrey, Cui, Zishan et al. (2024). "Does This Patient Have Alcohol Use Disorder?: The Rational Clinical Examination Systematic Review.". JAMA. DOI: 10.1001/jama.2024.3101 [abstract-verified: yes]
  • [1] Yue, Yihua, Rothberg, Michael B, Back, Sudie E et al. (2026). "Rates of Diagnosis and Treatment for Alcohol Use Disorder Among All of Us Participants with Unhealthy Alcohol Use.". J Gen Intern Med. DOI: 10.1007/s11606-025-10089-5 [abstract-verified: partial]

Replacement Resolution Audit

Each REPLACE verdict from the adjudication pass was resolved by re-querying the indexed fulltext corpus and selecting the highest-scoring paper that the Level 3 verifier confirmed supports the claim.

  • [9][3] (verifier: partial; score 0.85). Title: _The impact of DSM classification changes on the prevalence of alcohol use disorder and 'diagnostic orphans' in Lebanese _
  • [9][7] (verifier: partial; score 0.74). Title: Identifying Alcohol Use Disorder and Problem Use in Adult Primary Care Patients: Comparison of the Tobacco, Alcohol, Pre
  • [10][6] (verifier: partial; score 0.97). Title: Cognitive Impairments in Early-Detoxified Alcohol-Dependent Inpatients and Their Associations with Socio-Demographic, Cl
  • [2][1] (verifier: partial; score 0.82). Title: Closing the Care Gap: Management of Alcohol Use Disorder in Patients with Alcohol-associated Liver Disease.
  • [2][11] (verifier: partial; score 0.82). Title: Equivalence of Alcohol Use Disorder Symptom Assessments in Routine Clinical Care When Completed Remotely via Online Pati
  • [2][12] (verifier: partial; score 0.62). Title: Racial/ethnic disparities in alcohol-related problems: differences by gender and level of heavy drinking.
  • [2][13] (verifier: partial; score 0.77). Title: Agile implementation of alcohol screening in primary care.
  • [2][14] (verifier: partial; score 0.78). Title: _Practical assessment of DSM-5 alcohol use disorder criteria in routine care: High test-retest reliability of an Alcohol _
  • [2][15] (verifier: yes; score 0.67). Title: Comparison of Substance Use Disorder Diagnosis Rates From Electronic Health Record Data With Substance Use Disorder Prev
  • [16][2] (verifier: yes; score 0.69). Title: Rates of Diagnosis and Treatment for Alcohol Use Disorder Among All of Us Participants with Unhealthy Alcohol Use.
  • [16]NO REPLACEMENT FOUND (considered 3 candidates; none verified)
  • [16][2] (verifier: partial; score 0.56). Title: Rates of Diagnosis and Treatment for Alcohol Use Disorder Among All of Us Participants with Unhealthy Alcohol Use.
  • [9][17] (verifier: partial; score 0.82). Title: Practice facilitation to promote evidence-based screening and management of unhealthy alcohol use in primary care: a pra
  • [18][4] (verifier: yes; score 0.74). Title: Differences in the Prevalence and Profile of DSM-IV and DSM-5 Alcohol Use Disorders-Results from the Singapore Mental He
  • [18]NO REPLACEMENT FOUND (considered 5 candidates; none verified)
  • [14][3] (verifier: partial; score 0.85). Title: _The impact of DSM classification changes on the prevalence of alcohol use disorder and 'diagnostic orphans' in Lebanese _
  • [14][19] (verifier: partial; score 0.77). Title: Poor subjective sleep predicts compromised quality of life but not cognitive impairment in abstinent individuals with Al
  • [14][20] (verifier: partial; score 0.64). Title: _Implementing Technology-Supported Care for Depression and Alcohol Use Disorder in Primary Care in Colombia: Preliminary _
  • [10][21] (verifier: partial; score 0.68). Title: Alcohol use during pregnancy: the impact of social determinants of health on alcohol consumption among pregnant women.
  • [22][8] (verifier: partial; score 0.84). Title: Psychosocial treatment options for adolescents and young adults with alcohol use disorder: systematic review and meta-an
  • [22][23] (verifier: partial; score 0.71). Title: Demographic differences in the cascade of care for unhealthy alcohol use: A cross-sectional analysis of data from the 20
  • [15][2] (verifier: partial; score 0.82). Title: Rates of Diagnosis and Treatment for Alcohol Use Disorder Among All of Us Participants with Unhealthy Alcohol Use.

References

1.Closing the Care Gap: Management of Alcohol Use Disorder in Patients with Alcohol-associated Liver Disease.Layer B
Green, Ellen W, Byers, Isabelle S, Deutsch-Link, Sasha (2023). Clin Ther. DOI PubMed
2.Rates of Diagnosis and Treatment for Alcohol Use Disorder Among All of Us Participants with Unhealthy Alcohol Use.Layer B
Yue, Yihua, Rothberg, Michael B, Back, Sudie E et al. (2026). J Gen Intern Med. DOI PubMed
3.The impact of DSM classification changes on the prevalence of alcohol use disorder and 'diagnostic orphans' in Lebanese college youth: Implications for epidemiological research, health practice, and policy.Layer B
Ghandour, Lilian A, Anouti, Sirine, Afifi, Rima A (2020). PLoS One. DOI PubMed
4.Differences in the Prevalence and Profile of DSM-IV and DSM-5 Alcohol Use Disorders-Results from the Singapore Mental Health Study 2016.Layer B
Subramaniam, Mythily, Abdin, Edimansyah, Kong, Alexander Man Cher et al. (2022). Int J Environ Res Public Health. DOI PubMed
5.The natural history of DSM-5 alcohol-use disorder from late adolescence to middle adulthood in Australia: a prospective cohort study.Layer A
Kerr, Jessica A, Husin, Hanafi Mohamad, Leung, Janni et al. (2025). Lancet Public Health. DOI PubMed
6.Cognitive Impairments in Early-Detoxified Alcohol-Dependent Inpatients and Their Associations with Socio-Demographic, Clinical and Psychological Factors: An Exploratory Study.Layer B
Caneva, Stefano, Ottonello, Marcella, Torselli, Elisa et al. (2020). Neuropsychiatr Dis Treat. DOI PubMed
7.Identifying Alcohol Use Disorder and Problem Use in Adult Primary Care Patients: Comparison of the Tobacco, Alcohol, Prescription Medication and Other Substance (TAPS) Tool With the Alcohol Use Disorders Identification Test Consumption Items (AUDIT-C).Layer B
Adam, Angéline, Laska, Eugene, Schwartz, Robert P et al. (2025). Subst Use Addctn J. DOI PubMed
8.Psychosocial treatment options for adolescents and young adults with alcohol use disorder: systematic review and meta-analysis.Layer A
Belay, Getaneh Mulualem, Mak, Yim Wah, Wong, Frances Kam Yuet et al. (2024). Front Public Health. DOI PubMed
9.Primary care management of alcohol use disorder and at-risk drinking: Part 1: screening and assessment.Layer B
Sheryl Spithoff, Meldon Kahan (2015). Canadian family physician Medecin de famille canadien. PubMed
10.Does This Patient Have Alcohol Use Disorder?: The Rational Clinical Examination Systematic Review.Layer A
Wood, Evan, Pan, Jeffrey, Cui, Zishan et al. (2024). JAMA. DOI PubMed
11.Equivalence of Alcohol Use Disorder Symptom Assessments in Routine Clinical Care When Completed Remotely via Online Patient Portals Versus In Clinic via Paper Questionnaires: Psychometric Evaluation.Layer B
Matson, Theresa E, Lee, Amy K, Oliver, Malia et al. (2024). J Med Internet Res. DOI PubMed
12.Racial/ethnic disparities in alcohol-related problems: differences by gender and level of heavy drinking.Layer B
Witbrodt, Jane, Mulia, Nina, Zemore, Sarah E et al. (2014). Alcohol Clin Exp Res. DOI PubMed
13.Agile implementation of alcohol screening in primary care.Layer B
Summanwar, Diana, Ropert, Chelan, Barton, James et al. (2024). BMC Prim Care. DOI PubMed
14.Practical assessment of DSM-5 alcohol use disorder criteria in routine care: High test-retest reliability of an Alcohol Symptom Checklist.Layer B
Hallgren, Kevin A, Matson, Theresa E, Oliver, Malia et al. (2022). Alcohol Clin Exp Res. DOI PubMed
15.Comparison of Substance Use Disorder Diagnosis Rates From Electronic Health Record Data With Substance Use Disorder Prevalence Rates Reported in Surveys Across Sociodemographic Groups in the Veterans Health Administration.Layer A
Williams, Emily C, Fletcher, Olivia V, Frost, Madeline C et al. (2022). JAMA Netw Open. DOI PubMed
16.Diagnostic Criteria for Identifying Individuals at High Risk of Progression From Mild or Moderate to Severe Alcohol Use Disorder.Layer A
Miller, Alex P, Kuo, Sally I-Chun, Johnson, Emma C et al. (2023). JAMA Netw Open. DOI PubMed
17.Practice facilitation to promote evidence-based screening and management of unhealthy alcohol use in primary care: a practice-level randomized controlled trial.Layer B
Huffstetler, Alison N, Kuzel, Anton J, Sabo, Roy T et al. (2020). BMC Fam Pract. DOI PubMed
18.DSM-5 and ICD-11 alcohol use disorder criteria in young adult regular drinkers: Lifetime prevalence and age of onset.Layer B
Slade, Tim, Mewton, Louise, O'Dean, Siobhan et al. (2021). Drug Alcohol Depend. DOI PubMed
19.Poor subjective sleep predicts compromised quality of life but not cognitive impairment in abstinent individuals with Alcohol Use Disorder.Layer B
Piekarski, David, Sullivan, Edith V, Pfefferbaum, Adolf et al. (2022). Alcohol. DOI PubMed
20.Implementing Technology-Supported Care for Depression and Alcohol Use Disorder in Primary Care in Colombia: Preliminary Findings.Layer B
Torrey, William C, Cepeda, Magda, Castro, Sergio et al. (2020). Psychiatr Serv. DOI PubMed
21.Alcohol use during pregnancy: the impact of social determinants of health on alcohol consumption among pregnant women.Layer B
Peltier, MacKenzie R, Verplaetse, Terril L, Bici, Vera et al. (2025). Biol Sex Differ. DOI PubMed
22.Addiction Medicine: Alcohol Use Disorder.Layer B
Grissom, Maureen O, Reed, Brian C, Starks, Steven M et al. (2024). FP Essent. PubMed
23.Demographic differences in the cascade of care for unhealthy alcohol use: A cross-sectional analysis of data from the 2015-2019 National Survey on Drug Use and Health.Layer B
Mintz, Carrie M, Knox, Justin, Hartz, Sarah M et al. (2023). Alcohol Clin Exp Res (Hoboken). DOI PubMed